Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line

Biochemical and Biophysical Research Communications

Volumn 302, Issue 1, 2003, Pages 46-55

  Zeng, Huiyan ^a   Datta, Kaustubh ^a   Neid, Matthias ^a   Li, Jinping ^a   Parangi, Sareh ^a   Mukhopadhyay, Debabrata ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; PROTEIN KINASE P60; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN;

ADENOCARCINOMA; ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUTATION; ONCOGENE RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 0037470435     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00107-4     Document Type: Article

References (58)

1. Tomaszewska R. Morphologic, morphometric and immunohistochemical studies on pancreatic intraductal hyperplasia and infiltrating carcinoma. Folia Med Cracov. 40:1999;101-141.
2. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control. 7:2000;421-427.
3. Watanabe M., Nobuta A., Tanaka J., Asaka M. An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int. J. Cancer. 67:1996;264-268.
4. Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C., Neoptolemos J., Williamson R.C. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer. 64:1991;1076-1082.
5. Ozawa F., Friess H., Tempia-Caliera A., Kleeff J., Buchler M.W. Growth factors and their receptors in pancreatic cancer. Teratog. Carcinog. Mutagen. 21:2001;27-44.
6. Maehara N., Matsumoto K., Kuba K., Mizumoto K., Tanaka M., Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer. 84:2001;864-873.
7. TannoMitsuuchi S.Y., Altomare D.A., Xiao G.H., Testa J.R. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 61:2001;589-593.
8. Lohr M., Schmidt C., Ringel J., Kluth M., Muller P., Nizze H., Jesnowski R. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61:2001;550-555.
9. Bergmann U., Funatomi H., Yokoyama M., Beger H.G., Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55:1995;2007-2011.
10. Pawson T., Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science. 278:1997;2075-2080.
11. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta. 1332:1997;F105-F126.
12. Ozer E., Ozkal S., Karademir S., Sagol O., Sokmen S., Coker A., Kupelioglu A., Astarcioglu I. Angiogenesis and p53 and H-ras mutations in pancreatic ductal adenocarcinoma. Anal. Quant. Cytol. Histol. 21:1999;473-476.
13. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
14. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
15. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 6:1991;1677-1683.
16. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269:1994;26988-26995.
17. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., Pan Y.C., Olander J.V., Connolly D.T., Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172:1990;1535-1545.
18. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149:1996;293-305.
19. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L.J.J., Delfino, Siegel N.R., Leimgruber R.M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1989;1470-1478.
20. Spyridopoulos I., Brogi E., Kearney M., Sullivan A.B., Cetrulo C., Isner J.M., Losordo D.W. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J. Mol. Cell Cardiol. 29:1997;1321-1330.
21. Phillips G.D., Stone A.M., Jones B.D., Schultz J.C., Whitehead R.A., Knighton D.R. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 8:1994;961-965.
22. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 88:2000;2239-2245.
23. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:2000;737-744.
24. Schwarte-Waldhoff I., Volpert O.V.N.P., Bouck, Sipos B., Hahn S.A., Klein-Scory S., Luttges J., Kloppel G., Graeven U., Eilert-Micus C., Hintelmann A., Schmiegel W. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. USA. 97:2000;9624-9629.
25. Zeng H., Dvorak H.F., Mukhopadhyay D. VPF/VEGF receptor-1 down modulates VPF/VEGF receptor-2 mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase dependent pathways. J. Biol. Chem. 276:2001;26969-26979.
26. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
27. Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110:1997;2293-2302.
28. Dunn S.E. Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor. Growth Horm. IGF Res. 10(Suppl A):2000;S41-S42.
29. ′ -kinase and distinct from that induced by hypoxia Cancer Res. 60:2000;5879-5886.
30. Narita T., Taga T., Sugita K., Nakazawa S., Ohta S. The autocrine loop of epidermal growth factor receptor-epidermal growth factor / transforming growth factor-alpha in malignant rhabdoid tumor cell lines: heterogeneity of autocrine mechanism in ttc549. Jpn. J. Cancer Res. 92:2001;269-278.
31. Presta M., Rusnati M., Dell'Era P., Tanghetti E., Urbinati C., Giuliani R., Leali D. Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. Adv. Exp. Med. Biol. 476:2000;7-34.
32. Ulrich C.D. 2nd Growth factors, receptors, and molecular alterations in pancreatic cancer. Putting it all together. Med. Clin. North Am. 84:2000;697-705. xi-xii.
33. de Jong J.S., van Diest P.J., van der Valk P., Baak J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J. Pathol. 184:1998;53-57.
34. Mira E., Manes S., Lacalle R.A., Marquez G., Martinez A.C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology. 140:1999;1657-1664.
35. Dunn S.E., Ehrlich M., Sharp N.J., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J.C.A. dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58:1998;3353-3361.
36. Long L., Rubin R., Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp. Cell Res. 238:1998;116-121.
37. Clark J.W., Santos-Moore A., Stevenson L.E., Frackelton A.R. Jr. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway. Int. J. Cancer. 65:1996;186-191.
38. Bouterfa H.L., Sattelmeyer V., Czub S., Vordermark D., Roosen K., Tonn J.C. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res. 20:2000;2761-2771.
39. Giehl K., Skripczynski B., Mansard A., Menke A., Gierschik P. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K- ras: implications for cell proliferation and cell migration. Oncogene. 19:2000;2930-2942.
40. Kijima H., Scanlon K.J. Ribozyme as an approach for growth suppression of human pancreatic cancer. Mol. Biotechnol. 14:2000;59-72.
41. Giehl K., Seidel B., Gierschik P., Adler G., Menke A. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene. 19:2000;4531-4541.
42. Sato T., Konishi K., Kimura H., Maeda K., Yabushita K., Tsuji M., Miwa A. Evaluation of PCNA, p53, K-ras and LOH in endocrine pancreas tumors. Hepatogastroenterology. 47:2000;875-879.
43. Ellenrieder V., Adler G., Gress T.M. Invasion and metastasis in pancreatic cancer. Ann. Oncol. 10:1999;46-50.
44. Lazar-Molnar E., Hegyesi H., Toth S., Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 12:2000;547-554.
45. Guirouilh J., Castroviejo M., Balabaud C., Desmouliere A., Rosenbaum J. Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int. J. Oncol. 17:2000;777-781.
46. Datta K., Nambudripad R., Pal S., Zhou M., Cohen H.T., Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J. Biol. Chem. 275:2000;20700-20706.
47. Flossmann-Kast B.B., Jehle P.M., Hoeflich A., Adler G., Lutz M.P. Src stimulates insulin-like growth factor I (IGF)-I-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res. 58:1998;3551-3554.
48. Cheung N., Wong M.P., Yuen S.T., Leung S.Y., Chung L.P. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum. Pathol. 29:1998;910-914.
49. Viglietto G., Maglione D., Rambaldi M., Cerutti J., Romano A., Trapasso F., Fedele M., Ippolito P., Chiappetta G., Botti G.et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 11:1995;1569-1579.
50. Plate K.H., Risau W. Angiogenesis in malignant gliomas. Glia. 15:1995;339-347.
51. Itakura J., Ishiwata T., Shen B., Kornmann M., Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer. 85:2000;27-34.
52. Pal S., Datta K., Khosravi-Far R., Mukhopadhyay D. Role of PKC z in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 1:2000;1.
53. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375:1995;577-581.
54. Kim Y.B., Han J.Y., Kim T.S., Kim P.S., Chu Y.C. Overexpression of c-H-ras p21 is correlated with vascular endothelial growth factor expression and neovascularization in advanced gastric carcinoma. J. Gastroenterol. Hepatol. 15:2000;1393-1399.
55. Mukhopadhyay D., Akbarali H.I. Depletion of [Ca2+]i inhibits hypoxia-induced vascular permeability factor (vascular endothelial growth factor) gene expression. Biochem. Biophys. Res. Commun. 229:1996;733-738.
56. Ellis L.M., Staley C.A., Liu W., Fleming R.Y., Parikh N.U., Bucana C.D., Gallick G.E. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem. 273:1998;1052-1057.
57. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:1997;5328-5335.
58. Lopez T., Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4:2002;339-353.